文献速递眼底病与葡萄膜炎

康柏西普治疗新生血管性年龄相关性黄斑变性:随机III期PHOENIX研究结果

Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study.
PubMed 文献 · Am J Ophthalmol · 2018-08-24

PHOENIX研究为前瞻性双盲多中心假注射对照III期随机试验,评估0.5 mg康柏西普玻璃体腔注射(3次每月后每季度一次)治疗AMD继发CNV的疗效与安全性。共114例(91.9%)完成12个月研究。3个月时康柏西普组BCVA平均较基线提升9.20字母,假注射组提升2.02字母(P < .001);12个月时两组分别提升9.98和8.81字母(P = .64)。

要点

  • 康柏西普3+Q3M方案在3个月时BCVA提升显著优于假注射组。
  • 12个月时两组BCVA提升相近,但假注射组前3月后转为康柏西普治疗。
  • 最常见眼部不良事件为结膜出血和眼压升高,与玻璃体腔注射相关。

核心结论

  • 康柏西普初始3次每月注射后每季度一次的治疗方案对AMD有效。
  • 既往其他抗VEGF药物在相同方案下未能维持类似临床获益。

研究设计与样本

  • 前瞻性、双盲、多中心、假注射对照的III期随机试验。
  • 纳入AMD继发脉络膜新生血管患者,随机分入康柏西普组或假注射对照组。
  • 康柏西普组前3月每月注射0.5 mg,之后每季度一次至12月(3+Q3M)。
  • 假注射组前3月每月假注射,随后3次每月康柏西普0.5 mg注射,之后每季度一次至12月。
  • 主要终点为第3月BCVA较基线平均变化。

主要发现

  • 共114例(91.9%)来自中国9个中心完成12个月研究。
  • 第3月BCVA平均变化:康柏西普组+9.20字母,假注射组+2.02字母(P < .001)。
  • 第12月BCVA平均变化:康柏西普组+9.98字母,假注射组+8.81字母(P = .64)。
  • 最常见眼部不良事件为结膜出血和眼压升高,与玻璃体腔注射相关。

关键数值与推荐

  • 康柏西普剂量为0.5 mg,前3月每月一次,之后每季度一次至12月。

临床怎么用

  • 康柏西普可采用3次每月负荷后每季度一次方案治疗AMD继发CNV。
  • 治疗中需监测结膜出血和眼压升高等注射相关不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Age-related macular degeneration (AMD) can cause irreversible vision loss leading to blindness. We aim to evaluate the efficacy and safety of intravitreal injections of 0.5 mg conbercept, a new anti-vascular endothelial growth factor (anti-VEGF) drug, for treatment of AMD on a schedule more manageable for patients. DESIGN: A prospective, double-masked, multicenter, sham-controlled, phase III randomized trial. METHODS: Patients: Patients with choroidal neovascularization (CNV) secondary to AMD were enrolled and randomized to the conbercept group or the sham control group. INTERVENTION: The conbercept group received intravitreal injections of conbercept (0.5 mg) once monthly for the first 3 months, then once quarterly until month 12 (3 + Q3M). The sham group received first 3 monthly sham injections and then 3 monthly injections of conbercept (0.5 mg) followed by quarterly administrations until month 12. MAIN OUTCOME MEASURES: The primary endpoint was mean change from baseline in best-corrected visual acuity (BCVA) at month 3. RESULTS: A total of 114 patients (91.9%) from 9 sites in China completed the 12-month study. At the 3-month primary endpoint, the mean changes in BCVA from baseline were +9.20 letters in the conbercept group and +2.02 letters in the sham group, respectively (P < .001). At 12 months, the mean changes from baseline in BCVA letter score were +9.98 letters in the conbercept group and +8.81 letters in the sham group (P = .64). The most common ocular adverse events were associated with intravitreal injections, such as conjunctival hemorrhage, and increased intraocular pressure. CONCLUSIONS: A conbercept dosing regimen of 3 initial monthly administrations followed by quarterly treatments is effective for treatment of AMD. In previous reports, other anti-VEGF agents were unable to maintain similar clinical benefits with the same regimen.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Liu K, Song Y, Xu G, et al. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. Am J Ophthalmol. 2018. PMID: 30148987. doi:10.1016/j.ajo.2018.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。